Back to top
more

Gilead Sciences (GILD)

(Delayed Data from NSDQ)

$83.61 USD

83.61
5,456,718

+0.57 (0.69%)

Updated Sep 27, 2024 04:00 PM ET

After-Market: $83.61 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Madhu Goel headshot

4 Biotech Bets to Watch as Industry Rebounds in a Month

The biotech sector makes a sharp rise in 30 days post the positive data read out from Biogen's mid-stage Alzheimer's trial on BAN2401. We recommend a few industry players for investors' portfolio boost.

    5 Biotech Stocks Well Poised to Beat Q2 Earnings Estimates

    Biotech industry experiences a turnaround in June. Here are five stocks which are expected to beat expectation in Q2.

      J&J's Darunavir-Based Single-Tablet HIV Regimen Gets FDA Nod

      The FDA approves Johnson and Johnson's (JNJ) darunavir-based single-tablet regimen, Symtuza, for the treatment of type 1 HIV-1 in treatment-naive and certain virologically suppressed adults.

        The Zacks Analyst Blog Highlights: Mastercard, Gilead, Goldman Sachs, PepsiCo and Aetna

        The Zacks Analyst Blog Highlights: Mastercard, Gilead, Goldman Sachs, PepsiCo and Aetna

          Is Invesco Zacks Multi-Asset Income ETF (CVY) a Hot ETF Right Now?

          Smart Beta ETF report for CVY

            Sweta Killa headshot

            Biotech ETFs Surge on Biogen's Positive Drug Trial Result

            Biotech ETFs surge on Biogen's encouraging Phase 2 clinical study data for Alzheimer???s treatment.

              Mark Vickery headshot

              Top Research Reports for Mastercard, Gilead & Goldman Sachs

              Today's Research Daily features new research reports on 16 major stocks, including Mastercard (MA), Gilead (GILD) and Goldman Sachs (GS).

                Ryan McQueeney headshot

                Why Biotech Stocks Rallied on Biogen's Alzheimer's Test

                Several major biotech stocks rallied on Friday after Biogen (BIIB) reported positive results from a Phase 2 study of its Ban2401 therapy, which seeks to reduce toxic amyloid proteins associated with cognitive decline and Alzheimer's disease.

                  Biotech Stock Roundup: GILD's Positive CHMP Nod, Regulatory Updates & More

                  Key headlines in the biotech sector last week include Gilead getting positive CHMP opinion, Keryx plunging on merger news while Celgene and Amgen came out with pipeline updates.

                    Is Gilead Sciences a Great Stock for Value Investors?

                    Let's see if Gilead Sciences Inc. (GILD) stock is a good choice for value-oriented investors right now from multiple angles.

                      Novartis to Spin-Off Alcon as Separate Trading Company

                      Novartis announces that it will spin-off its ophthalmology division, Alcon, into a separately-traded standalone company in order to focus on its legacy pharmaceuticals business.

                        Gilead's (GILD) CAR T Therapy Gets Positive CHMP Opinion

                        Gilead (GILD) obtains positive opinion from the CHMP for its MAA for CAR T therapy, axicabtagene ciloleucel, as a treatment for DLBCL and PMBCL.

                          Ekta Bagri headshot

                          4 Biotech Stocks to Bet on in the Second Half of 2018

                          While the first half did not turn out to be great for the biotech sector, the second half is expected to be much better. Here, we list four biotechs poised for a good run.

                            Biotech Stock Roundup: PBYI Soars, MACK Crashes, GILD's Biktarvy Gets EC Nod

                            The biotech sector was in the news with a few hits and misses. Gilead's Biktarvy got approval in Europe while Puma Biotechology is also closer to breast cancer drug approval in Europe.

                              Gilead's (GILD) Biktarvy Gets EC Nod for HIV- 1 Infection

                              Gilead's (GILD) HIV portfolio gets a further boost with the European Commission's approval of Biktarvy for HIV-1 infection.

                                Kevin Cook headshot

                                CRISPR Science and Stocks: Knowing Enough to Invest

                                Can you learn enough about the science and the companies to invest with confidence?

                                  Novartis Announces Positive Data on CAR-T Therapy, Kymriah

                                  Novartis (NVS) announces positive results on Kymriah from the JULIET TRIAL in patients with relapsed or refractory diffuse large B-cell lymphoma.

                                    Zacks Value Investor Highlights: Gilead Sciences, Biogen, Celgene, Lannett and Valeant

                                    Zacks Value Investor Highlights: Gilead Sciences, Biogen, Celgene, Lannett and Valeant

                                      Ekta Bagri headshot

                                      NASH Space in Focus as Galmed (GLMD) Posts Positive Data

                                      Investor focus is back on the NASH space as quite a few companies release promising data on their NASH candidates of late.

                                        Tracey Ryniec headshot

                                        Drug Stocks: The Next Hot Industry or Value Traps?

                                        These 5 stocks look dirt cheap but is it too good to be true?

                                          Galmed (GLMD) Soars on Positive NASH Data on Aramchol

                                          Shares of Galmed Pharmaceuticals (GLMD) surges significantly following positive top-line results on lead candidate Aramchol in NASH patients.

                                            Indrajit Bandyopadhyay headshot

                                            JAK Inhibitors' Prospects Strong: 4 Stocks Ruling the Space

                                            Given the growing interest in JAK-inhibitor based treatments, here's a look at some companies that are looking to change the ways to treat autoimmune diseases.

                                              Gilead Collaborates with Hookipa for HBV and HIV Therapies

                                              Gilead Sciences (GILD) collaborates with Hookipa Biotech AG for the development of immunization technologies for HBV and HIV diseases.

                                                Biotech Stock Roundup: Regeneron, Celgene, Amgen Impress at ASCO

                                                The biotech sector was in focus last week due to the ASCO meet at Chicago where biotech bigwigs presented data on their oncology drugs and promising pipeline candidates.

                                                  Madrigal's NASH Study Data Encouraging, Stock Skyrockets

                                                  Madrigal Pharmaceuticals' (MDGL) thyroid hormone receptor, MGL-3196, achieves significantly sustained reduction in liver fat at week 36 in a phase II study evaluating it in NASH patients.